Picture [LSUS] – The Business Web Portal 600x60px
Document › Details

ProBioGen AG. (4/18/18). "Press Release: ProBioGen Signs Second Contract Development Agreement with Tizona Therapeutics for Immuno-Oncology Antibody Project". Berlin.

Organisations Organisation ProBioGen AG
  Group Minapharm (Group)
  Organisation 2 Tizona Therapeutics Inc.
Products Product CHO.Right® development and manufacturing platform
  Product 2 antibody cancer drug
Index term Index term Tizona Therapeutics–Minapharm: biopharma production, 201804– supply service cell line + process developm + production of therap antibody by ProBioGen
Persons Person O’Brien, Christine (Tizona Therapeutics 201804 VP Program Management)
  Person 2 Sandig, Volker (ProBioGen 201004 promoted CSO since 2000 at ProBiogGen before Merck US)

ProBioGen AG, a premier service & technology provider for complex therapeutic glycoproteins, today announced that it has signed a second clinical immuno-oncology development and manufacturing agreement with Tizona Therapeutics, Inc., a privately held immunology company, harnessing the power of the immune system to develop treatments for cancer.

Under the terms of the agreement, ProBioGen is developing a stable cell line, followed by process development and GMP clinical manufacturing for Tizona’s lead antibody drug candidate.

“Tizona Therapeutics selected ProBioGen based on its excellent CHO.Right® development and manufacturing platform,” said Christine O’Brien, Vice President of Program Management at Tizona Therapeutics. “ProBioGen’s collaborative approach, high standard for delivering quality product and timely execution of our project again make them an ideal partner for Tizona.”

Dr. Volker Sandig, ProBioGen’s Chief Scientific Officer added, “ProBioGen’s and Tizona’s teams work together really well and ProBioGen is committed to delivering a quality product candidate within best-in-class development timelines to support potential clinical trials for Tizona Therapeutics.”

About ProBioGen

ProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins.
Combining both state-of-the-art development services, based on ProBioGen’s CHO-RiGHT® expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.

Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.

All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).

ProBioGen was founded 1994, is privately owned, and located in Berlin, Germany.


Dr. Gabriele Schneider
Chief Business Officer
ProBioGen AG
Goethestr. 54
13086 Berlin, Germany
+49 (0)30 924 006-0

Record changed: 2018-04-25


Picture [LSA] – The Business Web Portal 650x89px

More documents for Minapharm (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px

» top